Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Express Scripts
Mallinckrodt
AstraZeneca
Dow

Last Updated: February 2, 2023

Celgene Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Celgene

Drugs and US Patents for Celgene

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-004 Feb 8, 2013 RX Yes Yes 9,993,467*PED See Plans and Pricing Y See Plans and Pricing
Celgene Intl ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-001 Mar 25, 2020 RX Yes No 9,382,217 See Plans and Pricing See Plans and Pricing
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-004 Jun 29, 2006 AB RX Yes Yes 7,465,800 See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Celgene

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-003 Feb 8, 2013 6,315,720 See Plans and Pricing
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-006 Jun 5, 2013 6,045,501 See Plans and Pricing
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-001 Feb 8, 2013 8,626,531 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for CELGENE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 10 mg/vial ➤ Subscribe 2013-11-05
➤ Subscribe Capsules 1 mg, 2 mg, 3 mg and 4 mg ➤ Subscribe 2017-02-08
➤ Subscribe Capsules 5 mg, 10 mg and 15 mg ➤ Subscribe 2010-08-30
➤ Subscribe Capsules 50 mg and 100 mg ➤ Subscribe 2006-12-18
➤ Subscribe Capsules 150 mg ➤ Subscribe 2014-02-03
➤ Subscribe Capsules 25 mg ➤ Subscribe 2010-07-12
➤ Subscribe Capsules 2.5 mg and 20 mg ➤ Subscribe 2016-07-12
➤ Subscribe Capsules 200 mg ➤ Subscribe 2006-09-25

Supplementary Protection Certificates for Celgene Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2913326 C20200031 00353 Estonia See Plans and Pricing PRODUCT NAME: OSANIMOOD;REG NO/DATE: EU/1/20/1442 25.05.2020
2291080 2020/042 Ireland See Plans and Pricing PRODUCT NAME: OZANIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR OZANIMOD HYDROCHLORIDE.; REGISTRATION NO/DATE: EU/1/20/1442 20200525
2291080 CA 2020 00047 Denmark See Plans and Pricing PRODUCT NAME: OZANIMOD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER OZANIMODHYDROCHLORID; REG. NO/DATE: EU/1/20/1442 20200520
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Baxter
Mallinckrodt
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.